Ophthalmic drugs are preparations used for the treatment of eye diseases and disorders such as cataract, glaucoma, color blindness, diabetic macular edema, CMV retinitis, and age-related macular degeneration. The ophthalmic drugs market is witnessing significant growth, due to increase in prevalence of eye disorders and rise in use of combination therapies for treatment of ophthalmic disorders, especially glaucoma. Combination therapies have various advantages over traditional medication such improvement in patient compliance and efficacy. Moreover, surge in prevalence of ophthalmic disorders, rise in geriatric population globally, and change in demographics fuel the ophthalmic drugs market growth. The global ophthalmic drugs market was valued at $29,613 million in 2016, and is expected to reach $42,663 million by 2023, registering a CAGR of 5.3% from 2017 to 2023.
The ophthalmic drugs market is segmented based on indication, type, distribution channel, dosage form, technology, therapeutic class, and geography. Depending on indication, the market is divided into dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. On the basis of type, the market is bifurcated into prescription drugs and over-the-counter drugs. By distribution channel, it is categorized into hospital pharmacies, online pharmacies, drug stores, and others. According to dosage form, it is classified into liquid ophthalmic drug forms, semisolid ophthalmic drug forms, solid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. As per technology, the market is segmented into biologics, cell therapy, gene therapy, drug delivery, small molecule, and others. Based on therapeutic class, it is classified into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, and anti-allergy drugs. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
As per ophthalmic drugs market analysis, in the recent years, Asia-Pacific reported significant growth in the ophthalmic drugs market, owing to steady increase in the prevalence of glaucoma in the Asian population. In addition, increase in the number of people suffering from primary angle-closure glaucoma in Japan, China, and South Korea supplement this growth further.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global ophthalmic drugs market with the current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of the factors that drive and restrict the market growth is provided.
Comprehensive quantitative analysis of the industry is provided from 2016 to 2023 to assist stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps in understanding the trends in types and technologies globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
By Indication
Dry Eye
Glaucoma
Infection/Inflammation/Allergy
Retinal Disorders
Wet Age-related Macular Degeneration
Dry Age-related Macular Degeneration
Diabetic Retinopathy
Others
Others
By Type
Prescription Drugs
Over-the-Counter Drugs
By Dosage Form
Liquid Ophthalmic Drug Forms
Solid Ophthalmic Drug Forms
Semisolid Ophthalmic Drug Forms
Multicompartment Drug Delivery Systems
Other Ophthalmic Drug Forms
By Technology
Biologics
Cell Therapy
Gene Therapy
Drug Delivery
Small Molecule
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores
Online Pharmacies
Others
By Therapeutic Class
Anti-glaucoma
Anti-infection
Anti-inflammatory
Anti-allergy
By Geography
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Turkey
Saudi Arabia
Rest of LAMEA
KEY MARKET PLAYERS
Santen Pharmaceutical Co., Ltd.
Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.)
Shire Plc
Alcon (Novartis)
Genentech, Inc.
Allergan, Plc
Sun Pharmaceutical Industries Limited
Actavis Generics (Teva Pharmaceutical Industries Ltd.)
Regeneron Pharmaceuticals, Inc.
Pfizer Inc.
The other players in the value chain include (profiles not included in the report)
Abbott Medical Optics, Inc.
Carl-Zeiss AG
Ellex Medical Lasers Ltd.
Essilor International S.A.
Hoya Corporation
Insight Vision Inc.
Nidek Co. Ltd.
Novagali Pharma S A
Topcon Corporation
Ziemer Ophthalmic Systems AG
